TrialCurveCAPTAIN-1st: reconstructed Kaplan–Meier curves
Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical Trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | JAMA Oncol. 2026 Jan 29;12(3):295–302. doi: 10.1001/jamaoncol.2025.6245 |
|---|---|
| DOI | 10.1001/jamaoncol.2025.6245 |
| Registry | NCT03707509 |
| Phase | Phase 3 |
| Conditions | Nasopharyngeal Carcinoma |
| Interventions | Camrelizumab, Placebos, Gemcitabine, Cisplatin |
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Enrolment | 263 |
| Source licence | Figure published under CC BY 4.0 |
Overall survival — Intention-to-treat population
From figure panel · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Camrelizumab group 34.4 months; Placebo group 26.5 months. Survival at 18 months: Camrelizumab group 76%; Placebo group 67%. Hazard ratio Camrelizumab group vs Placebo group 0.73 (95% CI 0.54–0.98).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Camrelizumab group | 134 | 85 | 34.4 |
| Placebo group | 129 | 95 | 26.5 |
- Camrelizumab group vs Placebo group: reconstructed HR 0.73 (95% CI 0.54–0.98)
Landmark survival (reconstructed)
| Time | Camrelizumab group | Placebo group |
|---|---|---|
| 6 mo | 93.3% | 96.1% |
| 12 mo | 84.3% | 79.8% |
| 18 mo | 76.0% | 66.7% |
| 24 mo | 68.4% | 52.6% |
| 36 mo | 46.3% | 41.4% |
| 48 mo | 39.3% | 29.6% |
| 60 mo | 37.6% | 24.2% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.74, reconstructed 0.729 pass
Overall survival — Camrelizumab group, by plasma EBV DNA clearance in the first 3 treatment cycles
From figure panel · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Undetectable 50.5 months; Detectable 27.6 months. Survival at 18 months: Undetectable 85%; Detectable 58%. Hazard ratio Undetectable vs Detectable 0.30 (95% CI 0.17–0.54).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Undetectable | 69 | 37 | 50.5 |
| Detectable | 20 | 18 | 27.6 |
- Undetectable vs Detectable: reconstructed HR 0.30 (95% CI 0.17–0.54)
Landmark survival (reconstructed)
| Time | Undetectable | Detectable |
|---|---|---|
| 6 mo | 97.1% | 95.0% |
| 12 mo | 88.4% | 85.0% |
| 18 mo | 85.5% | 58.4% |
| 24 mo | 78.1% | 58.4% |
| 36 mo | 60.4% | 15.9% |
| 48 mo | 50.1% | 5.3% |
| 60 mo | 46.8% | — |
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- KEYNOTE-048 (Japanese subgroup, 5-year): Overall survival; Progression-free survival (PFS)
- NRG-HN004: Progression-free survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials